Corporate News
2025
Total Voting Rights
30 April 2020
Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 161,295,607 ordinary shares of £0.00037 each.
The total issued share capital of the Company consists of 161,295,607 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Polarean Imaging plc | www.polarean.com/www.polarean-ir.com |
Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
David Hignell / Soltan Tagiev (Corporate Finance) | |
Vadim Alexandre / Rob Rees (Corporate Broking) | |
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
Paul McManus / Anna Dunphy | Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 |
2024
Total Voting Rights
30 April 2020
Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 161,295,607 ordinary shares of £0.00037 each.
The total issued share capital of the Company consists of 161,295,607 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Polarean Imaging plc | www.polarean.com/www.polarean-ir.com |
Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
David Hignell / Soltan Tagiev (Corporate Finance) | |
Vadim Alexandre / Rob Rees (Corporate Broking) | |
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
Paul McManus / Anna Dunphy | Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 |
2023
Total Voting Rights
30 April 2020
Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 161,295,607 ordinary shares of £0.00037 each.
The total issued share capital of the Company consists of 161,295,607 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Polarean Imaging plc | www.polarean.com/www.polarean-ir.com |
Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
David Hignell / Soltan Tagiev (Corporate Finance) | |
Vadim Alexandre / Rob Rees (Corporate Broking) | |
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
Paul McManus / Anna Dunphy | Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 |
2022
Total Voting Rights
30 April 2020
Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 161,295,607 ordinary shares of £0.00037 each.
The total issued share capital of the Company consists of 161,295,607 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Polarean Imaging plc | www.polarean.com/www.polarean-ir.com |
Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
David Hignell / Soltan Tagiev (Corporate Finance) | |
Vadim Alexandre / Rob Rees (Corporate Broking) | |
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
Paul McManus / Anna Dunphy | Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 |
2021
Total Voting Rights
30 April 2020
Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 161,295,607 ordinary shares of £0.00037 each.
The total issued share capital of the Company consists of 161,295,607 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Polarean Imaging plc | www.polarean.com/www.polarean-ir.com |
Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
David Hignell / Soltan Tagiev (Corporate Finance) | |
Vadim Alexandre / Rob Rees (Corporate Broking) | |
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
Paul McManus / Anna Dunphy | Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 |
2020
Total Voting Rights
30 April 2020
Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 161,295,607 ordinary shares of £0.00037 each.
The total issued share capital of the Company consists of 161,295,607 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Polarean Imaging plc | www.polarean.com/www.polarean-ir.com |
Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
David Hignell / Soltan Tagiev (Corporate Finance) | |
Vadim Alexandre / Rob Rees (Corporate Broking) | |
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
Paul McManus / Anna Dunphy | Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 |
2019
Total Voting Rights
30 April 2020
Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 161,295,607 ordinary shares of £0.00037 each.
The total issued share capital of the Company consists of 161,295,607 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Polarean Imaging plc | www.polarean.com/www.polarean-ir.com |
Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
David Hignell / Soltan Tagiev (Corporate Finance) | |
Vadim Alexandre / Rob Rees (Corporate Broking) | |
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
Paul McManus / Anna Dunphy | Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 |
2018
Total Voting Rights
30 April 2020
Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 161,295,607 ordinary shares of £0.00037 each.
The total issued share capital of the Company consists of 161,295,607 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Polarean Imaging plc | www.polarean.com/www.polarean-ir.com |
Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
David Hignell / Soltan Tagiev (Corporate Finance) | |
Vadim Alexandre / Rob Rees (Corporate Broking) | |
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
Paul McManus / Anna Dunphy | Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 |
Latest News
-
Taiwanese distributor agreement with Sumtage
03 February 2025 -
Key Patent in China Secured
30 January 2025 -
Polarean and SimonMed Announce Collaboration to Advance Lung Imaging Innovation
28 January 2025
About Us
Latest Annual Report
Investor Alert
Sign up for Email Alerts